The Effect of Cyclooxygenase-2 Inhibition on Renal Hemodynamic Function in Humans With Type 1 Diabetes
Open accessThe DOI matches its Crossref record.
Abstract
OBJECTIVE—Studies in animal models suggest that cyclooxygenase-2 (COX2) plays a role in the regulation of the renal microcirculation in diabetes. Accordingly, we examined the role of COX2 in the control of renal hemodynamic function and in the renal response to hyperglycemia in humans with uncomplicated type 1 diabetes. We hypothesized that COX2 inhibition would alleviate the hyperfiltration state and would abrogate the hyperglycemia-mediated rise in glomerular filtration rate (GFR). RESEARCH DESIGN AND METHODS—Renal function was assessed during clamped euglycemia and hyperglycemia on 2 consecutive days before and then again after 14 days of COX2 inhibition using 200 mg celecoxib once daily by mouth. For analysis, the cohort was then divided into two groups based on the baseline GFR: 9 subjects exhibited hyperfiltration (GFR ≥135 ml/min per 1.73 m2), and 12 subjects exhibited normofiltration (GFR <135 ml/min per 1.73 m2). RESULTS—Under euglycemic conditions, COX2 inhibition resulted in a significant decline in GFR in the hyperfiltration group (150 ± 5 to 139 ± 5 ml/min per 1.73 m2) but increased GFR in the normofiltration group (118 ± 5 to 138 ± 5 ml/min per 1.73 m2). COX2 inhibition did not blunt the hyperglycemia-associated rise in GFR in the normofiltration group and was instead associated with an augmented rise in GFR. CONCLUSIONS—In summary, our results support the hypothesis that COX2 is an important determinant of renal hemodynamic function in subjects with type 1 diabetes. The renal response to COX2 inhibition emphasizes that hyperfiltration and normofiltration are distinct physiological states.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Self-citationGlomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., van Bommel, E. J., Heerspink, H. J. L., van Raalte, D. H., & Joles, J. A. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060666 · Cited by 887
Mullens, W., Damman, K., Testani, J. M., Martens, P., Mueller, C., Lassus, J., Tang, W. H. W., Skouri, H., Verbrugge, F. H., Orso, F., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1697 · Cited by 411
Nonsteroidal Anti-Inflammatory Drugs and the Kidney
Hörl, W. H. (2010) · Pharmaceuticals · doi:10.3390/ph3072291 · Cited by 298
“In normotensive, normoalbuminuric adolescents and young adults with type 1 diabetes, COX-2 inhibition resulted in a significant decline in GFR in the hyperfiltration group but increased GFR in the normofiltration group [105], indicating that the renal hemodynamic response to COX-2 inhibition is dependent on GFR.”
BackgroundKidokoro, K., Cherney, D. Z. I., Bozovic, A., Nagasu, H., Satoh, M., Kanda, E., Sasaki, T., & Kashihara, N. (2019) · Circulation · doi:10.1161/circulationaha.118.037418 · Cited by 283
Self-citationRenal adverse effects of nonsteroidal anti-inflammatory drugs
Harirforoosh, S., & Jamali, F. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903311023 · Cited by 261
Pathophysiology of the Diabetic Kidney
Vallon, V., & Komers, R. (2011) · Comprehensive Physiology · doi:10.1002/cphy.c100049 · Cited by 259
Metadata
- Authors
- Cherney, D. Z. I., Miller, J. A., Scholey, J. W., Bradley, T. J., Slorach, C., Curtis, J. R., Dekker, M. G., Nasrallah, R., Hébert, R. L., & Sochett, E. B.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2008-03-01
- Volume
- 57
- Issue
- 3
- Pages
- 688-695
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2153286340
- Cited by
- 90
- References
- 0
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.